FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...
LIVERPOOL have reportedly enquired about the possibility of signing Mexican wonderkid Gilberto Mora from Club Tijuana. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results